Jan Klatt

Jan Klatt

Auto-generated profile, based on publicly available information

Jan Klatt

Novartis Pharma AG, Basel, Switzerland

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 January 2021 in Journal of Neurology, Neurosurgery & Psychiatry
Verified
Journal Article
Open access
PDF file
MLMichel Lantéri-Minet
Michel Lantéri-Minet
Peter GoadsbyPeter Goadsby
Peter Goadsby
URUwe Reuter
Uwe Reuter
SWShihua Wen
Shihua Wen
PHPeggy Hours-Zesiger
Peggy Hours-Zesiger
JKJan Klatt
Jan Klatt
Objective To evaluate the effect of erenumab on patient-reported, functional outcomes in patients with episodic migraine (EM) in whom 2–4 preventives were not useful from the Phase 3b LIBERTY study. Methods As previously reported, 246 patients with EM with 2–4 prior failed preventives were randomised 1:1 to subcutaneous erenumab 140 mg or placebo every 4 weeks for 12 weeks. This analysis evaluated Migraine Physical Function Impact Diary (MPFID), Headache Impact Test (HIT-6) and Work Productivity and Activity Impairment (WPAI) scores at Week 12. P values were nominal without multiplicity adjustment. Results Erenumab significantly improved MPFID-Physical Impairment (PI) and Everyday Activities (EA) scores versus placebo (treatment difference (TD) (95% CI) MPFID-PI: −3.5 (−5.7 to –1.2) (p=0.003); MPFID-EA: −3.9 (−6.1 to –1.7)) (p<0.001) at 12 weeks. Patients on erenumab were more likely to have a ≥5-point reduction in MPFID score (OR vs placebo (95% CI) MPFID-EA: 2.1 (1.2 to 3.6); MPFID-PI: 2.5 (1.4 to 4.5)). A similar trend was observed for HIT-6 (TD: −3.0; p<0.001); significantly higher proportions of patients on erenumab reported a ≥5-point reduction (OR (95% CI): 2.4 (1.4 to 4.1)). In three out of four WPAI domains, erenumab showed improvement versus placebo. Conclusion At 12 weeks, erenumab was efficacious on functional outcomes in patients with EM in whom 2–4 preventives were not useful. Trial registration details ClinicalTrials.gov identifier: NCT03096834.

7 September 2010 in ADHD Attention Deficit and Hyperactivity Disorders
Verified
Journal Article
Closed access
PDF file
ESEberhard Schulz
Eberhard Schulz
CFChristian Fleischhaker
Christian Fleischhaker
KHKlaus Hennighausen
Klaus Hennighausen
PHPhilip Heiser
Philip Heiser
FHFrank Haessler
Frank Haessler
JKJan Klatt
Jan Klatt